First dose-expansion patient successfully received SB-007 SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations SB-007 granted FDA Fast Track designation,...
Gilde Gilde Healthcare Portfolio company SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007 for Stargardt Disease
First dose-expansion patient successfully received SB-007 SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations SB-007 granted FDA Fast Track designation,...
9. January 2026
Gilde Healthcare erwirbt einen Mehrheitsanteil an Physio CKI, einer physiotherapeutischen Praxisgruppe, von Kapital 1852
Der Private Equity Fonds von Gilde Healthcare gibt den Erwerb der Mehrheitsanteile an Physio CKI von Kapital 1852 bekannt. Physio CKI ist eine wachstumsstarke Gruppe von Physiotherapiepraxen mit Hauptsitz in...
22. December 2025
Gilde Gilde Healthcare Portfolio company SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007 for Stargardt Disease
First dose-expansion patient successfully received SB-007 SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations SB-007 granted FDA Fast Track designation,...
9. January 2026
Filter & Suche
Fondsstrategie :
Loading...
Das waren alles Artikel
8eb27edd85